Overview

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Participants With Parkinson's Disease (PD)

Status:
Active, not recruiting
Trial end date:
2022-09-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of ABBV-951 in participants with Parkinson's disease (PD).
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie